key: cord-0744096-isikz2ph authors: Duran, M. A. Climent; Vidal, N.; Pérez, S.; Méndez-Vidal, M. J.; Anguera, G.; Salas, I. Martinez; Gallardo, E.; Cuellar, M. A.; Soto, J. J.; Martín, A.; Domènech, M.; Rodriguez-Vida, A.; Casado, E. Almagro; Diaz-Mejía, N.; Kareaga, M. Martinez; Calvo, O. Fernandez; Guzmán, J. C. Villa; Vazquez, S.; Gonzalez del Alba, A.; Puente, J. title: 1572P The impact of COVID-19 pandemic on Spanish genitourinary (GU) cancer patients: SOGUG-COVID-19 study date: 2021-09-30 journal: Annals of Oncology DOI: 10.1016/j.annonc.2021.08.1565 sha: f76412ff9fe76c7ed23f58341e6ea324b1d8cb79 doc_id: 744096 cord_uid: isikz2ph nan Results: Median age was 68.4 y (range 17-100), 322 pts (87.3%) were male. Tumor origin was kidney in 82 pts (22.7%), urothelial in 110 (29.8%), prostate 198 (40.7%), testis in 17 (4.6%) and other in 5 (1.4%). 216 (58.5%) pts were receiving active treatment at the moment of the infection: 20 neo/adjuvant treatment and 196 metastatic/palliative treatment. 81 pts (22%) were receiving immuno-oncology (IO), 69 (18.7%) chemotherapy (CT), 36 (9.8%) tyrosine kinase inhibitors (TKI), 67 (18.2%) new anti-androgen therapy, and 101 (27.4%) were on steroids. Most frequent symptoms of COVID-19 were: cough in 138 pts (37.4%), with a median duration of 6.6 days; fever 176 (47.7%), median duration 5.76 days; dyspnea 119 (32.2%), asthenia 82 (22.2%), diarrhea 44 (11.9%) and myalgia 36 (9.8%). Laboratory abnormalities were common, 166 pts (45%) had lymphopenia and 137 (37.1%) D-dimer elevation. 153 (41.5%) presented pneumonia and 119 (32.3%) had patchy pulmonary infiltrates. 132 patients had to be hospitalized (35.8%) and 55 (14.9%) died. The presence of radiological findings, hospitalization and mortality were not related to sex or treatment with IO, CT, TKI or corticosteroids. Median age of pts with radiological pneumonia (72 vs 65.8; p<0.0001), patchy infiltrates (71.4 vs 76; p¼0.002), admitted to the ICU (75 vs. 67; p<0,0001) and died (76.1 vs 67.77; p<0,0001) was higher. Conclusions: Mortality secondary to COVID-19 was higher in GU cancer patients than that described in the general population. As described in other settings, age was the most important risk factor for COVID-19 severe outcomes regardless of tumor type or treatment. Clinical trial identification: NCT04578132. Legal entity responsible for the study: Spanish Oncology GenitoUrinary Group (SOGUG). Background: Cancer patients are one of the most affected by the current pandemic caused by SARS-CoV-2. Social inequalities influence the incidence rate of this disease, as we have seen in the high incidence in our center. In our study, we asked whether the last covid-19 treatment advances, the capacity for restructuring the health centers and their non-saturation, influences the cancer patients outcomes. Methods: Retrospective review of 189 cancer patients diagnosed in our center with COVID-19 from March 5, 2020 to February 28, 2021. Study data was collected and managed using REDCap. We compared COVID-19 diagnoses in first-wave cancer patients versus the full pandemic period until data cut-off, as well as patient characteristics and mortality rates. Conclusions: In our center, one of the worst hit by the coronavirus crisis in Spain, with a supersaturation of almost 250% in the middle of the first wave, we have verified how the knowledge of the behavior of this disease, improvements in its treatment and a multidisciplinary management in Oncology ward have led to a significant decrease in mortality, going from almost 50% in the first wave to less than 15%, despite having suffered the disease during the two subsequent waves a greater number of patients with metastatic disease. Legal entity responsible for the study: Medical Oncology Department, Hospital Universitario Infanta Leonor. Funding: Has not received any funding. Advisory Board: Roche; Financial Interests, Personal Invited Speaker: IPSEN; Financial Interests, Personal, Advisory Board: IPSEN; Financial Interests, Personal, Invited Speaker: Astellas; Financial Interests, Personal, Advisory Board: Astellas; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Invited Speaker: Janssen; Financial Interests, Personal, Advisory Board: Janssen; Financial Interests, Personal Advisory Board: EUSA; Financial Interests, Personal, Invited Speaker: Merck; Financial Interests, Personal, Advisory Board: Merck; Financial Interests, Personal, Invited Speaker: Sanofi; Financial Interests, Personal, Advisory Board: Sanofi; Financial Interests, Personal, Invited Speaker: Astra; Financial Interests, Personal Invited Speaker: Astellas; Financial Interests, Personal, Invited Speaker: Janssen; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: MSD; Non-Financial Interests, Personal, Other, Travel: BMS; Non-Financial Interests, Personal, Other, Travel: Pfizer; Non-Financial Interests Speaker and advisory role: Bayer; Financial Interests, Personal, Invited Speaker: Janssen; Financial Interests, Personal, Invited Speaker: Ipsen. G. Anguera: Financial Interests, Personal, Speaker's Bureau: Bristol-Myers Squibb; Financial Interests, Personal, Speaker's Bureau: Ipsen; Financial Interests, Personal, Speaker's Bureau: Janssen; Financial Interests, Personal, Speaker's Bureau: Novartis. E. Gallardo: Financial Interests, Personal, Other, Advisory role. Speaking role: Sanofi; Financial Interests, Personal, Other, Advisory role. Speaking role: Janssen; Financial Interests, Personal, Other, Advisory role Speaking role: Bayer; Financial Interests, Personal, Other, Advisory role. Speaking role: Roche; Financial Interests, Personal, Other, Advisory role. Speaking role: Ipsen; Financial Interests, Personal, Other, Advisory role Speaking role: EUSA Pharma; Financial Interests, Personal, Other, Advisory role. Speaking role: BMS; Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Other, Advisory role Speaking role: Daiichi Sankyo; Financial Interests, Personal, Advisory Role: Techdow; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Invited Speaker: Menarini; Financial Interests, Personal Invited Speaker: Leo Pharma; Financial Interests, Personal, Other, Writing review: Novartis; Financial Interests, Personal Clinical trials: Pfizer; Financial Interests, Institutional, Other, Clinical trials: Lilly; Financial Interests, Institutional, Other, Clinical trials: Pfizer-Merk; Financial Interests, Institutional, Other, Clinical trials: MSD; Financial Interests, Institutional, Other, Clinical trials: BMS; Financial Interests, Institutional, Other, Clinical trials: Bayer; Financial Interests, Institutional, Other, Clinical trials: Daiichi Sankyo; Financial Interests, Institutional, Other, Clinical trials: Roche; Financial Interests, Institutional, Other Clinical trials: Immunicum; Financial Interests, Institutional, Other, Clinical trials: Mediolanum; Financial Interests, Institutional, Other, Clinical trials: Clovis; Non-Financial Interests, Personal, Member, Vice-president of SOGUG: SOGUG. A. Martín: Financial Interests, Personal, Advisory Board: Janssen; Financial Interests Clinical trial: Aveo; Financial Interests, Institutional, Other, Clinical trial: Pfizer; Non-Financial Interests, Personal, Invited Speaker: SEOM; Non-Financial Interests, Personal, Invited Speaker: SOGUG; Non-Financial Interests, Personal, Invited Speaker: GEICO; Non-Financial Interests, Personal, Invited Speaker: Grupo Centro de Tumores Genitourinarios; Other, Personal, Other, Travel expenses: Pfizer; Other, Personal, Other, Travel expenses: Roche; Other, Personal, Other, Travel expenses: PharmaMar. A. Rodriguez-Vida: Financial Interests, Personal, Other, Honoraria you have directly received for any speaker, consultancy or advisory role or similar: Roche; Financial Interests, Personal, Other, Honoraria you have directly received for any speaker, consultancy or advisory role or similar: MSD; Financial Interests, Personal, Other, Honoraria you have directly received for any speaker, consultancy or advisory role or similar: Pfizer; Financial Interests, Personal, Other, Honoraria you have directly received for any speaker, consultancy or advisory role or similar: BMS; Financial Interests, Personal, Other, Honoraria you have directly received for any speaker, consultancy or advisory role or similar: Astellas; Financial Interests, Personal, Other, Honoraria you have directly received for any speaker, consultancy or advisory role or similar: Janssen; Financial Interests, Personal, Other, Honoraria you have directly received for any speaker, consultancy or advisory role or similar: Bayer; Financial Interests, Personal, Other, Honoraria you have directly received for any speaker, consultancy or advisory role or similar: Clovis; Financial Interests, Personal, Other, Honoraria you have directly received for any speaker, consultancy or advisory role or similar: AstraZeneca; Financial Interests, Personal, Other, Honoraria you have directly received for any speaker, consultancy or advisory role or similar: Sanofi; Financial Interests, Personal, Project Lead: Takeda; Financial Interests, Personal, Project Lead: Pfizer; Financial Interests, Personal, Project Lead: Merk. E. Almagro Casado: Financial Interests, Personal, Speaker's Bureau: PharmaMar; Non-Financial Interests, Personal, Principal Investigator, Principal investigator of several clinical trials: Sponsors. M. Martinez Kareaga: Financial Interests, Personal, Other, Honoraria you have directly received for any speaker, consultancy or advisory role or similar: MSD; Financial Interests, Personal, Other, Honoraria you have directly received for any speaker, consultancy or advisory role or similar: Bristol-Myers Squibb; Financial Interests, Personal, Other, Honoraria you have directly received for any speaker, consultancy or advisory role or similar: Roche. O. Fernandez Calvo: Financial Interests, Personal Pierre Fabre; Financial Interests, Personal, Invited Speaker: Ipsen; Financial Interests, Personal, Advisory Role: Astellas; Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Personal, Advisory Role: Pfizer; Financial Interests, Personal, Advisory Role: Ipsen; Financial Interests, Personal, Advisory Role: Bristol-Myers; Financial Interests, Personal, Advisory Role: EUSA Pharma Member of the Board of Directors: SOGUG. J.C. Villa Guzmán: Financial Interests, Personal, Other, Educational sessions: Pfizer; Financial Interests, Personal, Other, Educational sessions: AstraZeneca; Financial Interests, Personal, Other, Educational sessions Financial Interests, Personal, Other, Educational sessions: Novartis; Financial Interests, Personal, Other, Educational sessions: Sanofi; Financial Interests, Personal, Other, Educational sessions: Bristol Advisory Role: Sanofi/Aventis; Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Personal, Advisory Role: Pfizer; Financial Interests, Personal, Advisory Role: Astellas Pharma; Financial Interests, Personal, Advisory Role: Janssen; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Ipsen; Financial Interests, Personal, Advisory Role: Bayer; Financial Interests, Personal, Advisory Role: BMS; Financial Interests, Personal, Advisory Role: Eisai; Financial Interests, Personal, Advisory Role: Pierre Fabre; Financial Interests, Personal, Advisory Role: EUSA Pharma Travel and accommodation expenses: Astellas Pharma; Financial Interests, Personal, Other, Travel and accommodation expenses: Pfizer; Financial Interests, Personal, Other, Travel and accommodation expenses: Janssen; Financial Interests, Personal, Other, Travel and accommodation expenses: Sanofi; Financial Interests, Personal, Other, Travel and accommodation expenses: BMS; Financial Interests Travel and accommodation expenses: Roche; Financial Interests, Personal, Other, Travel and accommodation expenses: Ipsen. A. Gonzalez del Alba: Financial Interests, Personal, Advisory Role: Sanofi/Aventis; Financial Interests Financial Interests, Personal, Advisory Role: Pfizer; Financial Interests Advisory Role: Janssen; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Ipsen; Financial Interests, Personal, Advisory Role: Bayer; Financial Interests Advisory Role: EUSA Pharma; Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Other, Traver and accommodation expenses: Astellas Pharma; Financial Interests, Personal, Other, Traver and accommodation expenses: Pfizer; Financial Interests, Personal, Other, Traver and accommodation expenses: Janssen; Financial Interests, Personal, Other, Traver and accommodation expenses: Sanofi; Financial Interests, Personal, Other, Traver and accommodation expenses: Bristol-Myers Squibb; Financial Interests, Personal, Other, Traver and accommodation expenses: MSD; Financial Interests, Personal, Other, Traver and accommodation expenses: Roche; Financial Interests, Personal, Other, Traver and accommodation expenses Invited Speaker: Bayer; Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Invited Speaker: Eisai; Financial Interests, Personal, Advisory Board: Eisai; Financial Interests, Personal, Advisory Board: Ipsen; Financial Interests, Personal, Invited Speaker: Janssen; Financial Interests, Personal, Advisory Board: Janssen; Financial Interests, Personal Advisory Board: MSD; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Advisory Board: Roche; Non-Financial Interests, Institutional, Research Grant: Astellas; Non-Financial Interests We assessed mortality risk by COVID-19 (C19) infection among treated cancer patients (pts) and the impact of anti-cancer treatment (tx) on mortality. Methods: Optum de-identified Electronic Health Record dataset (2021-01-07 release) were used to find cancer pts with a C19 positive (ICD-9/10-CM codes U071/U072 or positive test result) or negative 8%) were positive for C19 and 19,424 (92.2%) negative. Among 1,636 matched pairs of positive/negative C19 pts, the odds ratio (OR) of 30-day mortality comparing C19 positive vs negative patients was 2.14 (95% CI: 0.71 e 6.52) Conclusions: C19 showed a trend towards increased 30-day mortality risk (not statistically significant), and increased overall mortality risk. Specific tx did not appear to modulate 30-day mortality due to C19. Legal entity responsible for the study Full or part-time Employment: Roche/Genentech; Financial Interests, Personal, Stocks/ Shares: Roche. P. Lambert: Financial Interests, Personal, Full or part-time Employment: Genentech/ Roche; Financial Interests, Personal, Stocks/Shares: Roche. K. Sarsour: Financial Interests, Personal, Full or part-time Employment: Roche/Genentech; Financial Interests Financial Interests, Personal, Stocks/Shares: Roche. R. Walls: Financial Interests, Personal, Full or part-time Employment: Hoffmann-La Roche; Financial Interests, Personal, Stocks/Shares: Hoffmann